Shares of Glenmark Pharmaceuticals Ltd jumped more than 4% on 10 December following the company’s announcement that the initial clinical data for its blood cancer medication indicated an 83% good response rate.  Glenmark’s blood cancer medication’s successful clinical trial depended on this encouraging discovery, which improved investor confidence.

Glenmark Pharmaceuticals reported in an exchange filing that the initial clinical data from the Phase 1 study of its Trispecific TREAT Antibody, ISB 2001, demonstrated a favourable safety profile, a high overall response rate (ORR), and durable responses in patients with multiple myeloma who had received extensive pretreatment.

Glenmark added that based on the statistics, ISB 2001 might perform well in comparison to authorised bispecific choices. 

Hang Quach, M.D., Professor of Haematology at the University of Melbourne and Director of Haematology at St. Vincent’s Hospital Melbourne, said, “These results are among the most impressive I have seen in this patient population. ISB 2001 has the potential to revolutionise the treatment landscape for heavily pretreated patients with multiple myeloma who have exhausted currently approved therapies.”

Glenmark Pharmaceuticals reported a consolidated profit of Rs 354.49 crore for the July–September quarter, a significant improvement over the company’s consolidated loss of Rs 180.3 crore for the same time in the previous fiscal year.

Compared to the same time in the previous fiscal year, Q2’s consolidated income from operations climbed to Rs 3,433.8 crore from Rs 3,207.37 crore.

At 12:16 pm, the shares of Glenmark Pharma were trading 2.18% higher at Rs 1,547.10 on NSE.

Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!